One distinguishing clinical feature is that acute flares of pruritus, urticaria, edema, or vesiculation are noted minutes after contact with the causative substances. Additionally, the patch-test ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Another related condition, aquagenic pruritus (AP), causes intense itching upon water contact. Here's what you need to know ...

A pruritus-free day was defined as the absence ... prior to unblinding with the WHO-ART dictionary. All resources with URTICARIA in their preferred term were selected. All medical resources ...

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

Report Ocean has published a new report on the Pruritus Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers a ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...